|
US6346611B1
(en)
*
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6232071B1
(en)
*
|
1990-06-11 |
2001-05-15 |
Gilead Sciences, Inc. |
Tenascin-C nucleic acid ligands
|
|
AU782620B2
(en)
*
|
1991-06-10 |
2005-08-11 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
US6762290B1
(en)
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
PT1198490E
(pt)
|
1999-07-14 |
2006-06-30 |
Alza Corp |
Lipopolimeros neutros e composicoes liposomais que contem os mesmos
|
|
WO2002026932A2
(en)
*
|
2000-09-26 |
2002-04-04 |
Duke University |
Rna aptamers and methods for identifying the same
|
|
EP1438321B1
(de)
*
|
2001-10-26 |
2010-05-26 |
Noxxon Pharma AG |
Modifizierte l-nukleinsäure
|
|
HRP20040406A2
(en)
*
|
2001-11-09 |
2005-02-28 |
Eyetech Pharmaceuticals |
Methods for treating ocular neovascular diseases
|
|
US7094410B2
(en)
*
|
2002-03-02 |
2006-08-22 |
The Scripps Research Institute |
DNA vaccine against proliferating endothelial cells and methods of use thereof
|
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
CN100337689C
(zh)
*
|
2002-07-24 |
2007-09-19 |
弗·哈夫曼-拉罗切有限公司 |
聚亚烷基二醇酸加合物
|
|
ATE516366T1
(de)
|
2002-07-25 |
2011-07-15 |
Archemix Corp |
Regulierte aptamer-therapeutika
|
|
US9303262B2
(en)
|
2002-09-17 |
2016-04-05 |
Archemix Llc |
Methods for identifying aptamer regulators
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2006050498A2
(en)
|
2004-11-02 |
2006-05-11 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
WO2004050899A2
(en)
|
2002-12-03 |
2004-06-17 |
Archemix Corporation |
Method for in vitro selection of 2’-substituted nucleic acids
|
|
RU2234097C1
(ru)
*
|
2003-03-05 |
2004-08-10 |
Московский областной научно-исследовательский клинический институт |
Способ диагностики саркомы капоши
|
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
|
EP1620547B1
(en)
|
2003-04-21 |
2014-06-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CL2004001996A1
(es)
*
|
2003-08-08 |
2005-05-06 |
Eyetech Pharmaceuticals Inc |
Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
HUE050481T2
(hu)
|
2004-02-12 |
2020-12-28 |
Archemix Llc |
Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
|
|
MXPA06011965A
(es)
*
|
2004-04-13 |
2007-04-17 |
Osi Eyetech Inc |
Conjugados biologicamente activos mejorados.
|
|
US7579450B2
(en)
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
AU2005282380A1
(en)
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
AU2006265896B2
(en)
|
2005-06-30 |
2012-05-31 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
JP2009510182A
(ja)
*
|
2005-07-28 |
2009-03-12 |
（オーエスアイ）アイテツク・インコーポレーテツド |
シクリトールリンカーポリマー抱合体
|
|
CA2620182A1
(en)
|
2005-08-22 |
2007-03-01 |
Dennis A. Carson |
Tlr agonists
|
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
|
|
EP1966242A1
(en)
*
|
2005-12-06 |
2008-09-10 |
Domantis Limited |
Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
|
|
EP1968643A2
(en)
*
|
2005-12-16 |
2008-09-17 |
Diatos |
Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
|
|
US20090175930A1
(en)
*
|
2006-01-11 |
2009-07-09 |
Nobuhiro Yagi |
Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball
|
|
DK1991275T3
(en)
|
2006-03-08 |
2014-12-08 |
Archemix Llc |
Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
|
|
EP2510946B1
(en)
|
2007-02-07 |
2015-08-05 |
The Regents of The University of California |
Conjugates of synthetic tlr agonists and uses therefor
|
|
US20110229498A1
(en)
|
2008-05-08 |
2011-09-22 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
|
WO2010065671A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
PT2414322T
(pt)
*
|
2009-03-20 |
2022-12-07 |
Egen Inc |
Derivados de poliamina
|
|
EP2504436A1
(en)
|
2009-11-23 |
2012-10-03 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
JP5927194B2
(ja)
*
|
2010-09-24 |
2016-06-01 |
マリンクロッド エルエルシー |
治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
|
|
WO2013153138A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
|
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
AU2013340414B2
(en)
|
2012-10-23 |
2019-05-02 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
AU2013361323B2
(en)
|
2012-12-19 |
2018-09-06 |
Caris Science, Inc. |
Compositions and methods for aptamer screening
|
|
CA2907636C
(en)
|
2013-03-22 |
2018-02-06 |
The University Of Tokyo |
Aptamer to il-17 and use thereof
|
|
SI4374873T1
(sl)
|
2013-07-12 |
2026-01-30 |
Astellas Us Llc |
Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
|
|
BR112016004153A2
(pt)
|
2013-08-28 |
2019-09-17 |
Caris Life Sciences Switzerland Holdings Gmbh |
"método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
|
|
CN106999511A
(zh)
|
2014-12-11 |
2017-08-01 |
拜耳医药保健有限责任公司 |
具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
|
|
HK1244030A1
(en)
|
2014-12-29 |
2018-07-27 |
东丽株式会社 |
Composition containing nucleic acid molecule stably
|
|
US20180066262A1
(en)
|
2015-03-09 |
2018-03-08 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
WO2017004243A1
(en)
|
2015-06-29 |
2017-01-05 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
AU2017235661B2
(en)
|
2016-03-18 |
2023-06-08 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
|
IL298701B2
(en)
|
2016-05-25 |
2024-03-01 |
Caris Science Inc |
Oligonucleotide probes and uses thereof
|
|
EP3332812A1
(en)
|
2016-12-07 |
2018-06-13 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Nucleic acid-based assembly and use of the assembly in cancer therapy
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
TW201906635A
(zh)
|
2017-07-04 |
2019-02-16 |
日商第一三共股份有限公司 |
伴隨視細胞變性的視網膜變性的疾病用藥
|
|
WO2019210097A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Vitrisa Therapeutics, Inc. |
Aptamers with stability, potency or half-life for enhanced safety and efficacy
|
|
GB202405551D0
(en)
|
2024-04-19 |
2024-06-05 |
Vvb Bio Pte Ltd |
Combination treatment
|
|
WO2026159121A1
(en)
|
2025-01-22 |
2026-07-30 |
VVB Bio Pte. Ltd. |
Bispecific molecules
|